跳至主要内容
临床试验/ACTRN12608000462381
ACTRN12608000462381招募中未知

Paediatric Haemofiltration priming and anticoagulation methods - does additional heparinsed albumin priming, citrate or heparin anticoagulation produce the longest circuit lifetimes?

The Royal Childrens' Hospital Mebourne0 个研究点目标入组 100 人开始时间: 2008年9月16日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
o limit 至 15 Years(—)
性别
All

入选标准

  • Any patient requiring Continuous Veno-venus Haemofiltration (CVVH) in the unit will be eligible for the trial. Parental consent will be obtained before the patient is recruited.

排除标准

  • Patients with liver failure defined for the purpose of this trial as INR (international normalized ratio) >3 despite clotting factor replacement (these patients often have the problems of metabolizing heparin and citrate and more severe coagulopathy) or known sensitivity to heparin (i.e. heparin-induced thrombocytopenia) will be excluded from the trial. Patients with significant risk of bleeding (those with intra cranial, cerebral or pulmonary haemorrhage or stroke) will also be excluded, however, coagulopathic or thrombocytopenic patients without significant bleeding will be included.
  • If parental consent cannot be obtained or is not given the child will not participate in the trial.

研究者

发起方
The Royal Childrens' Hospital Mebourne

相似试验